TBP.DSG2tm1e mice were generated by crossing BRafCA, PtenloxP, Tyr::CreERT2 (TBP) mice with the conditional knockout DSG2.tm1e mice. Generation of the parental strains is outlined below.
BRafCA, PtenloxP, Tyr::CreERT2 (TBP) mice: The Tyr::CreERT2 transgene was designed with the mouse tyrosinase promoter/enhancer regions upstream of a tamoxifen/4-hydroxytamoxifen-inducible CreERT2 fusion gene (Cre recombinase fused to a G400V/M543A/L544A triple mutation of the human estrogen receptor ligand binding domain). This transgene was microinjected into FVB/NJ fertilized oocytes. Mice from founder line 13 were found to have melanocyte specific cre activity and were backcrossed to C57BL/6J mice for at least 11 generations. Subsequently, the congenic strain was crossed to B6.129S4-Ptentm1Hwu and maintained as a double homozygote colony. The mice were then crossed to B6.129P2-Braftm1Mmcm mice to generate these triple mutant mice.
1. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr, You MJ, DePinho RA, McMahon M, Bosenberg M. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet. 2009 May;41(5):544-52. doi: 10.1038/ng.356. Epub 2009 Mar 12. PMID: 19282848
2. https://www.jax.org/strain/013590
DSG2.tm1e mice are a conditional knockout created by crossing the Dsg2fl/fl (Dsg2tmc1) mice to Tyr::CreERT2 mice which drive an inducible system for DSG2 deletion only in Melanocyte cells via administration of tamoxifen. Parental Dsg2fl/fl mice were derived from the breeding of the DSG2tma1 mice (with the gene trap cassette, FRT-flanked lacZ-neomycin cassette into intron 1 of the murine Dsg2 locus (Dsg2 EUCOMM Project 36372 clone EPD0156_5_E04) with universal Flpe1 deleter mice (Flpe1) which will remove the gene trap cassette.
Nickname: TBP-DSG2.tm1e
Location on chromosome (bp):
39580171-39702397 bp,
MGI Gene Accession ID
Please also use this link to determine if other mutants have been registered with MGI (Mouse Genome Informatics)
Mice are viable however 10-20% of mice develop spontaneous melanomas within 4 months with an increased risk as mice age due to leaky Cre recombinase expression and the genetic background which is less than the reported incidence for the BRafCA, PtenloxP, Tyr::CreERT2 parental strain on the JAX website.
Mice that are hemizygous for the Tg(Tyr-cre/ERT2)13Bos transgene, homozygous for BRafCA and homozygous for PtenloxP should develop melanoma lesions with tamoxifen application.
Phenotype Heterozygous State
Mice are viable however 10-20% of mice develop spontaneous melanomas within 4 months with an increased risk as mice age due to leaky Cre recombinase expression and the genetic background which is less than the reported incidence for the BRafCA, PtenloxP, Tyr::CreERT2 parental strain on the JAX website.
Mice that are hemizygous for the Tg(Tyr-cre/ERT2)13Bos transgene, homozygous for BRafCA and homozygous for PtenloxP should develop melanoma lesions with tamoxifen application.
Genetic Background Currently Maintained
C57Bl/6N
Strain identification
Fertility and Strain maintenance
Fertility and Strain maintenance
Female
Male
Are homozygous mice viable?
Unknown
Unknown
Are homozygous mice fertile?
Unknown
Unknown
Are heterozygotes / hemizygotes* fertile?
Unknown
Unknown
* Hemizygote as used here refers to males carring a mutation on the X chromosome or mice of either sex
carrying an inserted transgene with no homologous allele on the other chromosome.
Homozygous Matings Required?
No
Male Fertility Compromised?
No
Breeding Performance
Unknown
Relevant bibliographic / database references
General information
Associated IP rights?
Unknown
Does it Model a Human Condition?
Unknown
Is the strain available in any form to other researchers
